HSP90AB1 and metabolic dysfunction-associated steatotic liver disease: The Hsp90 inhibitor 17-AAG promotes the accumulation of albumosomes in vitro and in vivo, thus suppresses the progression of NAFLD and obesity in HFD-fed mice.